

## APA DSM-V Task Force Member Disclosure Report

Name : Philip S Wang M.D.  
Job Title : Director, Division of Services and Intervention Research, NIMH  
Address : 6001 Executive Blvd Room 7151 Msc 9629  
Bethesda MD 20892-0001  
Role : **Member**  
Date : **5/2/2011**

### Task Force:

Task Force on DSM-V

### Biographical Sketch

#### Biographical Sketch:

Philip S. Wang, M.D., Dr.P.H., is the Deputy Director of the National Institute of Mental Health. He completed his undergraduate, medical school, psychiatry residency, as well as doctoral training in epidemiology, all at Harvard University. His research has focused on three areas: psychopharmacoeconomics; psychopharmacoeconomics; and mental health services research. He was the Principal Investigator of the NIMH-sponsored Work Outcomes Research and Cost-effectiveness Study (WORCS), a large-scale trial to examine the return-on-investment of enhanced depression care for workers. Dr. Wang has served as a voting member on the FDA Psychopharmacologic Drugs Advisory Committee, FDA Neurological Devices Panel, and FDA Endocrinologic and Metabolic Drugs Advisory Committee. He also served on the NIMH Services Research and Clinical Epidemiology Study Section. He is currently Chair of the WHO World Mental Health Study Services Research Work Group. He is a member of the American Psychiatric Association's DSM-V Task Force and has consulted on several APA Work Groups to develop evidence-based treatment guidelines. Dr. Wang is an author of approximately 180 scientific publications.

The table below represents the disclosure for Dr.Philip S Wang M.D. of significant interests and affiliations for the three years prior to the DSM Task Force or a DSM Work Group member nomination and the period prior to public announcement of his/her appointment. The table also represents the reported disclosures of significant interests and affiliations for the past full calendar year and the current year to date for Dr.Philip S Wang M.D..

Dr. Philip S Wang M.D. has agreed that, from the time of approval through the publication of DSM-V, projected in 2013, (his/her) aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed \$10,000 in any calendar year.

Commercial or Other Organization	Year(s)	Relationship	Key(s)
Phillips Lytle LLP (firm representing GSK)	2003 - 2005	Self	Consultation
Phillips Lytle LLP	2004 - 2005	Self	Expert Testimony
Innovus, Inc	2003 - 2005	Self	Consultation
Collegium Internationale Psychopharmacologicum	2005 - 2005	Self	Honoraria
Best Practices, Inc.	2006 - 2006	Self	Honoraria

The table below represents the reported disclosures of uncompensated leadership positions with Non-Profit or Advocacy Organizations that may have a direct or indirect interest in psychiatric diagnosis, treatment, or the DSM-V for the three years prior to appointment and the current year to date for Philip S Wang M.D..

Non-Profit or Advocacy Organization	Year(s)	Relationship	Role
-------------------------------------	---------	--------------	------

None